RxDoctor Payments Data

Michael Caplan, MD

Internal Medicine · Danville, VANPI 1275572562

Payments from drug & device makers

$13,417in general payments, 2019–2025

Across 505 payments — averaging $26.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$6K
  • Novo Nordisk$807
  • Amgen$705
  • AbbVie$612
  • AstraZeneca$600
  • Pfizer$536
  • plus $5K from 46 others

What the payments were for

  • Speaking & faculty fees$4,73035%
  • Travel & lodging$901%
  • Food & beverage$8,54364%
  • Education$540%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,417 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$30,831
Medicare patients
259
Services billed
818

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide183$223,915
TrulicityDulaglutide162$202,332
EliquisApixaban196$162,697
JardianceEmpagliflozin149$162,050
XareltoRivaroxaban139$141,920
FarxigaDapagliflozin Propanediol160$127,022
JanuviaSitagliptin Phosphate73$93,106
Repatha SureclickEvolocumab65$53,511
RybelsusSemaglutide51$48,812
RexultiBrexpiprazole32$45,094
VascepaIcosapent Ethyl81$37,821
MyrbetriqMirabegron38$36,962
EntrestoSacubitril/Valsartan28$23,349
LinzessLinaclotide31$21,739
KerendiaFinerenone24$19,907

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$807$272,727234 claims
Lilly USA, LLCTrulicity$353$202,332162 claims
PfizerEliquis$536$162,697196 claims
Boehringer IngelheimJardiance$371$162,050149 claims
Johnson & JohnsonXarelto, Invokana$5,617$159,711151 claims
AstraZenecaFarxiga$600$127,022160 claims
MerckJanuvia$226$93,10673 claims
Otsuka America Pharmaceutical, Inc.Rexulti$22$45,09432 claims
Astellas Pharma US IncMyrbetriq$67$36,96238 claims
NovartisEntresto$449$23,34928 claims
AbbVieLinzess$612$21,73931 claims
BayerKerendia$269$19,90724 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,724 internal medicine providers in Virginia.

Other internal medicine in Danville

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →